BenchSci has developed two platforms, AI-Assisted Reagent Selection and AI-Assisted Antibody Selection, which provide researchers with specific information and help them select reagents and antibodies for their experiments. The platforms have been validated by independent organizations and are used by top pharmaceutical companies and thousands of research centers worldwide. The company has raised significant funding, including a recent Series B round of $22 million, and has been recognized for its impact and culture. BenchSci's vision is to accelerate drug discovery and bring medicine to patients 50% faster by 2025.